Ansys Announces Q1 Financial Results
GlobeNewswire
*/ **Q1* *2024** Results*· Revenue of $466.6 million
· GAAP diluted earnings per share of $0.40 and non-GAAP diluted..
*/ **Q1* *2024** Results*· Revenue of $466.6 million
· GAAP diluted earnings per share of $0.40 and non-GAAP diluted..
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports..
Dublin, March 05, 2024 (GLOBE NEWSWIRE) -- The "Collaboration Deals in Biotechnology 2019-2024" report has been added to *..